Global Trust Asset Management LLC bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 4th quarter, HoldingsChannel.com reports. The fund bought 12,525 shares of the biopharmaceutical company’s stock, valued at approximately $897,000.

A number of other hedge funds also recently made changes to their positions in GILD. Provident Investment Management Inc. boosted its stake in Gilead Sciences by 3.5% during the second quarter. Provident Investment Management Inc. now owns 376,731 shares of the biopharmaceutical company’s stock worth $26,665,000 after buying an additional 12,682 shares during the period. Shoker Investment Counsel Inc. boosted its stake in Gilead Sciences by 7.3% during the second quarter. Shoker Investment Counsel Inc. now owns 4,340 shares of the biopharmaceutical company’s stock worth $307,000 after buying an additional 294 shares during the period. Bienville Capital Management LLC boosted its stake in shares of Gilead Sciences by 18.3% in the second quarter. Bienville Capital Management LLC now owns 9,925 shares of the biopharmaceutical company’s stock valued at $702,000 after purchasing an additional 1,535 shares during the period. Freestone Capital Holdings LLC boosted its stake in shares of Gilead Sciences by 2.2% in the second quarter. Freestone Capital Holdings LLC now owns 282,543 shares of the biopharmaceutical company’s stock valued at $19,998,000 after purchasing an additional 6,027 shares during the period. Finally, IFM Investors Pty Ltd boosted its stake in shares of Gilead Sciences by 110.6% in the second quarter. IFM Investors Pty Ltd now owns 35,879 shares of the biopharmaceutical company’s stock valued at $2,540,000 after purchasing an additional 18,846 shares during the period. 77.96% of the stock is owned by institutional investors.

How to Become a New Pot Stock Millionaire

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) opened at $81.72 on Wednesday. The firm has a market cap of $106,186.01, a P/E ratio of 9.49, a P/E/G ratio of -1.86 and a beta of 1.24. Gilead Sciences, Inc. has a 1-year low of $63.76 and a 1-year high of $89.54. The company has a quick ratio of 2.67, a current ratio of 2.74 and a debt-to-equity ratio of 1.53.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, topping analysts’ consensus estimates of $1.67 by $0.11. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The company had revenue of $5.95 billion for the quarter, compared to analysts’ expectations of $5.71 billion. During the same quarter last year, the company earned $2.70 earnings per share. The firm’s revenue for the quarter was down 18.7% on a year-over-year basis. equities analysts forecast that Gilead Sciences, Inc. will post 6.21 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 29th. Shareholders of record on Friday, March 16th will be issued a dividend of $0.57 per share. The ex-dividend date is Thursday, March 15th. This represents a $2.28 dividend on an annualized basis and a yield of 2.79%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. Gilead Sciences’s dividend payout ratio (DPR) is presently 59.77%.

In other Gilead Sciences news, EVP James R. Meyers sold 100,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $80.24, for a total transaction of $8,024,000.00. Following the sale, the executive vice president now owns 102,715 shares of the company’s stock, valued at $8,241,851.60. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider John C. Martin sold 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $73.62, for a total transaction of $3,681,000.00. Following the sale, the insider now directly owns 3,046,766 shares in the company, valued at approximately $224,302,912.92. The disclosure for this sale can be found here. In the last three months, insiders have sold 430,268 shares of company stock worth $34,074,395. 1.30% of the stock is owned by corporate insiders.

Several research firms have recently commented on GILD. ValuEngine raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 8th. Credit Suisse Group set a $80.00 price objective on shares of Gilead Sciences and gave the company a “hold” rating in a research note on Wednesday, January 3rd. Leerink Swann lowered their price objective on shares of Gilead Sciences from $86.00 to $83.00 and set a “market perform” rating for the company in a research note on Wednesday, February 7th. Vetr raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.25 price objective for the company in a research note on Monday, February 19th. Finally, Barclays reissued an “overweight” rating and issued a $95.00 price objective (up previously from $90.00) on shares of Gilead Sciences in a research note on Tuesday, March 6th. One analyst has rated the stock with a sell rating, ten have given a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the stock. Gilead Sciences currently has a consensus rating of “Buy” and a consensus price target of $88.61.

ILLEGAL ACTIVITY NOTICE: This piece of content was published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.dailypolitical.com/2018/03/14/12525-shares-in-gilead-sciences-inc-gild-acquired-by-global-trust-asset-management-llc.html.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.